Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324 on ClinicalTrials.gov · last registry update 2026-04-15

A small phase 2 — 20 participants, against a typical 110. Due to report 1 April 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Appendicular lean muscle mass. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for cardiovascular disease and obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: The University of Texas Health Science Center at San Antonio
Sponsor type: Other
Enrollment: 20
Started: 2026-04-01
Primary completion: 2027-04-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Appendicular lean muscle mass

Conditions studied

Obesity Prevention · Sarcopenia in Elderly · Cardiovascular Function · GLP - 1 · Weight Loss

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.